Navigation Links
Anthera Pharmaceuticals Announces Departure of Georgina Kilfoil
Date:2/5/2013

HAYWARD, Calif., Feb. 5, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced that Senior Vice President of Product Development Georgina Kilfoil has notified the company she will leave the company effective February 15, 2013 to pursue other opportunities.

"The Board and management of Anthera would like to thank Georgina for her years of dedicated service. Georgina's exemplary leadership and experience was instrumental in the advancement of Anthera's development programs. Her tireless efforts brought us to the starting line of our BRIGHT-SC phase 2 study for IgA Nephropathy and CHABLIS-SC phase 3 study for systemic lupus erythematosus, which we are excited to get underway this year," said Paul F. Truex , Anthera's President and Chief Executive Officer. "We wish Georgina all the best as she seeks to repeat her success in future endeavors."

Dr. Colin Hislop , Anthera's Senior Vice President and Chief Medical Officer, will continue to oversee all product development related activities for blisibimod.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements about the Company's expectations with respect to it
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
2. Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
3. Anthera Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
4. Anthera Announces Additional Data from the Phase 2b PEARL-SC Presented at the ACR/ARHP 2012 Annual Scientific Meeting
5. Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting
6. Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)
7. Anthera Pharmaceuticals Reports 2012 Second Quarter Financial Results And Provides Clinical Progress Update
8. Anthera Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
9. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
10. Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
11. Anthera Pharmaceuticals Provides Additional Data from the Recently Completed PEARL-SC Study of Blisibimod in the Proposed Phase 3 Population
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... INDIANAPOLIS and LYON, France ... (NYSE: LLY ) and Adocia (Euronext Paris: ... focused on developing an ultra-rapid insulin, known as BioChaperone ... type 2 diabetes. BioChaperone Lispro relies on Adocia,s proprietary ... Lilly and Adocia will develop BioChaperone Lispro ...
(Date:12/17/2014)... , Dec. 17, 2014 Royal Philips ... Corporation (NASDAQ: VOLC ), a global leader in ... that they have entered into a definitive merger agreement. Pursuant ... acquire all of the issued and outstanding shares of Volcano ... price of USD 1 billion (approx. EUR 800 million), to ...
(Date:12/17/2014)... -- Revenue and earnings above the previous year ... In the past 2013/14 fiscal year (ended 30 ... EUR 4.287 billion (last year: EUR 4.190 billion) despite unfavorable ... 360 million. "Overall, 2013/14 was a successful fiscal year for ... and CEO of Carl Zeiss AG. "Thanks to our broad ...
Breaking Medicine Technology:Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8ZEISS Asserts its Position in Difficult Environment 2
... May 21, 2007/PRNewswire-FirstCall/ -- Bristol-Myers,Squibb Company (NYSE: ... which showed that treatment with Baraclude (entecavir),demonstrated ... 48 weeks,-- a result that was also ... These data from an open-label, randomized viral ...
... -- Data presented,today at a major medical meeting ... for five days is as,effective as standard therapy ... treatment of complicated urinary tract infections,(cUTI) and acute ... markets LEVAQUIN in the,U.S., presented the data during ...
Cached Medicine Technology:Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 2Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 3Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 4Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 5Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 6Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 2Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 3Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 4
(Date:12/21/2014)... December 21, 2014 Serious Buyer, Andrew ... 1967 Jm Morrison and the Doors International Ballroom at ... would also be the only time that Morrison's mother ... on Nov. 25, 1967. According to Hawley, “This would ... did play the Alexandria Roller Rink earlier that year ...
(Date:12/21/2014)... Columbus, OH (PRWEB) December 21, 2014 ... of men alleging heart attacks, stroke and blood clots ... continue to increase, a new study shows that the ... developing colon cancer. In a study published in the ... lead researcher, James Amos-Landgraf examined a group of male ...
(Date:12/20/2014)... 21, 2014 BambooIndustry.com is ... the business has announced its bamboo flooring promotion ... best material from certified suppliers, and offers the ... worldwide. In the current promotion, all customers can ... when they say they know BambooIndustry.com from press ...
(Date:12/20/2014)... New York, NY (PRWEB) December 20, 2014 ... ) that allege a metal-on-metal version of the ... move forward in state and federal courts, Bernstein ... in New Jersey’ Bergen County Superior Court on ... were permitted to begin deposition of plaintiffs on ...
(Date:12/20/2014)... 20, 2014 Angeldress.co.uk, the distinguished wedding ... for worldwide dress fans. The company has recently updated ... information. For the holiday season, Angeldress Blog ... wedding apparel. , Angeldress.co.uk prides itself in offering a ... of service. All the company’s outfits are very carefully ...
Breaking Medicine News(10 mins):Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 4Health News:Eco-friendy Bamboo Flooring Manufacturer BambooIndustry.com Introduces Its Bamboo Flooring Promotion for 2015 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 4Health News:Trendy Professional Wedding Apparel Recommended by Angeldress Blog 2
... Oct. 24 (HealthDay News) -- Roughly 10 percent of Americans ... that doing so increases their risk for three common skin ... In conducting the study, researchers tracked the tanning bed ... high school and college, and then when the women were ...
... team led by scientists from The University of Texas MD ... their quest to map the vast blood vessel network of ... of Oct. 24 in the Proceedings of the National ... the goal of using the vascular system to personalize cancer ...
... Furlong founded Parent Project Muscular Dystrophy (PPMD) in 1995 to ... dystrophy with both resources and hope. Now, Furlong has blazed ... She has spearheaded a partnership between PPMD and the Public ... Currents: Muscular Dystrophy, this month. The story of the partnership ...
... Jenifer Goodwin HealthDay Reporter , MONDAY, Oct. 24 ... the airways of children with autism that she says may ... While examining children with autism who came in for a ... can see down into the windpipe and the airways that ...
... related macular degeneration (AMD) is the leading cause of ... identified several relatively common genetic variants which together predict ... number of persons without the disease also have these ... able to clearly show a specific rare mutation called ...
... University,s Office of Intellectual Property and Commercialization and ... institution,s faculty and researchers for technologies they have ... inventors. Faculty recognized for these achievements represent ... of Applied and Natural Sciences, College of Liberal ...
Cached Medicine News:Health News:More Evidence Links Tanning Beds to Higher Skin Cancer Risk 2Health News:Blood vessel mapping reveals 4 new 'ZIP codes' 2Health News:Blood vessel mapping reveals 4 new 'ZIP codes' 3Health News:Patient advocacy groups turn to open-access publishing to advance research quest 2Health News:Could Airway Abnormality Point to Autism? 2Health News:Could Airway Abnormality Point to Autism? 3Health News:Researchers ID genetic mutation associated with high risk of age-related macular degeneration 2Health News:Louisiana Tech University recognizes innovators, inventors 2Health News:Louisiana Tech University recognizes innovators, inventors 3
... to facilitate an arthrodesis, either by an ... cages allowing radicular compression by restoring the ... of the foramina, which in turn enhances ... major lumbar instabilities.,CC cages are made of ...
... The PACHETT 3 uses the exact enhanced ... the DGH pachymeters used exclusively by the ... built into the software. The new backlit ... running average, standard deviation and IOP correction ...
... Already, the most advanced motor driven ... easier and faster to learn and operate. ... maintaining accuracy and precision. Our software makes ... easy transition from manual instruments or other ...
The Medmont C100 Colour Vision Tester is an electronic colour vision screening device which is used to rapidly detect red/green colour vision deficiencies. Its high sensitivity provides a positive in...
Medicine Products: